Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Great dividend stocks should offer a mix of durability, solid income generation, and growth prospects. Read more to see 2 ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

South Korea-based Hanmi Pharmaceutical has reported positive outcomes from a Phase I/II clinical trial of Tivumecirnon ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

As advertisers pay more for an ever-scarcer supply of ratings points, pharma’s ironclad devotion to TV could finally be in ...

In the U.S., Dupixent remains the leader in new to brand prescription share across ... a setting in which KEYTRUDA failed and over the longer-term could represent a blockbuster opportunity ...

Standard treatment for stage III or stage IV clear cell renal cell carcinoma is surgery followed by immunotherapy with Merck's (MRK.N), opens new tab Keytruda ... women's athleisure brand 5: ...